Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2009
Date:10/19/2009

ults from the MADIT-CRT trial, which clearly demonstrated that CRT-D therapy slows the progression of heart failure, and we completed enrollment in the PLATINUM workhorse trial evaluating our next-generation PROMUS® Element(TM) Everolimus-Eluting Coronary Stent System. We also obtained key product approvals, including CE Mark for the LATITUDE Patient Management System and FDA approval of the TAXUS® Liberte® Long Paclitaxel-Eluting Coronary Stent System. These developments are further evidence of the strength and promise of our CRM and Cardiovascular businesses."

Guidance for Fourth Quarter and Full Year 2009

The Company estimates net sales for the fourth quarter of 2009 of between $2.025 billion and $2.125 billion. Adjusted earnings -- excluding acquisition-related credits, restructuring and restructuring-related costs, and amortization expense -- are estimated to range between $0.17 and $0.21 per share. The Company estimates net income on a GAAP basis of between $0.20 and $0.25 per share.

The Company has updated its net sales estimate for the full year of 2009 to between $8.134 billion and $8.234 billion. The Company now expects adjusted earnings for the full year -- excluding intangible asset impairment charges; acquisition-, divestiture-, and litigation-related net charges; restructuring and restructuring-related costs; discrete tax items; and amortization expense -- of between $0.75 and $0.79 per share. The Company expects net income on a GAAP basis of between $0.43 and $0.48 per share.

Boston Scientific officials will be discussing these results with analysts on a conference call at 8:00 a.m. (ET) Tuesday, October 20. The Company will webcast the call to all interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one y
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
2. Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Covered Stents
3. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
4. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
5. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
6. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress
8. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
9. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
10. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
11. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... board of directors of Eli Lilly and Company (NYSE: ... of 2015 of $0.50 per share on outstanding common stock. ... to shareholders of record at the close of business on ... is a global healthcare leader that unites caring with discovery ... were founded more than a century ago by a man ...
(Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
(Date:5/4/2015)... , May 4, 2015 PharmaEngine, ... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) with ... BAX ) jointly announced that Baxter has submitted ... Medicines Agency (EMA) for MM-398 (irinotecan liposome injection), ... adenocarcinoma of the pancreas who have been previously ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
... 18, 2012  UCB, a leading biopharmaceutical company committed to ... sponsor multiple sets of key epilepsy data at the ... (AAN) in New Orleans from April 21-28.  The data ... drug (AED) Vimpat® (lacosamide) C-V, including updated health-related quality ...
... 18, 2012  Sotera Wireless, Inc. announced that it has ... Drug Administration (FDA) for the ViSi Mobile™   System, ... in hospitals. The clearance represents a major milestone in ... system, particularly for ambulatory hospital patients. "Continuous ...
Cached Medicine Technology:UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 2UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 3UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 4UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 5UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 6UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 7UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 8UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 9Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 McNeil ... programs, announces the expansion of coverage for its ... leading provider of industry-tailored insurance and proactive risk management ... Company, we are dedicated to providing our customers with ... their many evolving needs. We are excited to launch ...
(Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be ... Group (RUG) Conference in Baltimore, MD from May 11 ... Group provides an opportunity for clients to gather to ... , In addition to sponsoring the event, TROY Healthcare ... RUG Conference. Attendees can stop by the TROY booth ...
(Date:5/4/2015)... American Telemedicine Association (ATA) today released an update to ... coverage and reimbursement, and physician practice standards and licensure. ... last September, many state regulating bodies responded by looking ... in their state,” said Jonathan Linkous, CEO of ATA. ... ATA reevaluated the indicators for each state and issued ...
(Date:5/4/2015)... Baptist Medical Center Jacksonville has ... With The Guidelines®-Stroke Gold Plus Quality Achievement Award ... award recognizes the hospital’s commitment and success in ... treatment according to nationally recognized, research-based guidelines based ... the Gold Plus Quality Achievement Award, hospitals must ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
... the London School of Hygiene, to access the preparation to ... that serious gaps in some national plans and big variations ... Romania, Poland and Portugal were the least prepared. It ... such a way that they need to collaborate with neighboring ...
... admitted on April 13 with a fever, swollen lymph nodes ... the bubonic plague that is a bacterial disease. // This ... the 14th century, killing up to one-third of the population. ... case in Los Angeles County in more than 22 years. ...
... common sight, though not a desirable one! Infact, obesity is ... Not surprising with all the high-calorie fast foods and soft ... television. ,Nationally recognized expert on child obesity, Dr. Goutham ... guide on “In Child Obesity: A Parent's Guide to a ...
... whose diet was Mediterranean, that included lots of fruits, ... dairy and meat, certainly had a low risk of ... published in the April issue of Annals of Neurology. ... , Alzheimer’s development is greatly influenced with diet pattern, ...
... elderly people turn to God as they approach death. This ... their earlier days.// The study, which appears in the March ... may actually increase the fear of dying in such people. ... hospice patients in North Central Florida all of who were ...
... estimates by United Nations are alarming that the actual ... around 70,000-80,000 (ranges are from 24,000 to 150,000).// ... during the quarter ending June 2004 was injecting drug ... (22.18 per cent), men who have sex with men ...
Cached Medicine News:Health News:Joint Effort among Various Nations to Tackle Bird Flu 2Health News:Bubonic Plague Confirmed In L.A. After More Than Two Decades 2
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used to occupy an empty hole which is not being used in an implantablepacemaker header....
Implantable medical grade silicone sleeve for adapting a 5 mm (01) connector to a 6 mm (02) connector....
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
Medicine Products: